Welcome, Guest. Please login or register.
March 29, 2024, 09:58:57 am

Login with username, password and session length


Members
  • Total Members: 6307
  • Latest: golfer
Stats
  • Total Posts: 55125
  • Total Topics: 4851
  • Online Today: 157
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 99
Total: 99

Welcome

Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Merck Drops Out of Hepatitis C Drug Development  (Read 5528 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
Merck Drops Out of Hepatitis C Drug Development
« on: October 20, 2017, 10:08:06 am »
Merck has announced that it is discontinuing development of new hepatitis C virus (HCV) medications, opting to focus on its approved treatment, Zepatier (grazoprevir/elbasvir).

The company had been researching two different combination treatments. One combined the NS3/4A protease inhibitor grazoprevir, which is already approved as a component of Zepatier, with two experimental direct-acting antivirals, the NS5A inhibitor ruzasvir and the NS5B polymerase inhibitor uprifosbuvir. Another combination included only the two experimental medications.

For more...
https://www.hepmag.com/article/merck-drops-hepatitis-c-drug-development

Offline Mugwump

  • Member
  • Posts: 778
  • My number of posts means nothing, piscor ergo sum!
Re: Merck Drops Out of Hepatitis C Drug Development
« Reply #1 on: October 23, 2017, 01:17:25 am »
This is discouraging news for those unfortunate individuals who have resistant strains that have failed the current treatments. Most likely it is the diminishing returns from the numbers who could become their customers which has caused this decision to stop development of new drugs. One also has to wonder whether or not payments to the holders of the patent on how DAA's are delivered directly to an hepatocyte has something to do with them getting out of the field. And how much cash actually changes hands for the right to use this method patent to create each new DAA.

All in all it is a very mysterious arrangement the way fair use patents on so called "intellectual property" of medical technology works these days. At least the cost for creating products from the  "intellectual property rights" around PCR RNA for HCV testing is finally starting to become a little more affordable for health care providers and HCV sufferers.
Caution shameless self promotion below :-)
https://www.hepmag.com/article/eric-reesor-27742-782589663
DING DONG MY DRAGON (HCV) IS FINALLY DEAD!

 


© 2024 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.